INHIBIKASE THERAPEUTICS
Inhibikase Therapeutics has developed the first small molecule platform capable of treating both bacterial and viral infectious disease through a common mechanism of action in the host. The Company's host targeting strategy creates multi-pathogen anti-infectives without stimulating resistance.
INHIBIKASE THERAPEUTICS
Industry:
Health Care Health Diagnostics Therapeutics
Founded:
2008-01-01
Address:
Atlanta, Georgia, United States
Country:
United States
Website Url:
http://www.inhibikase.com
Total Employee:
51+
Status:
Active
Contact:
617-936-0184
Total Funding:
1.27 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics
Similar Organizations
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
National Institute of Neurological Disorders and Stroke
National Institute of Neurological Disorders and Stroke investment in Grant - Inhibikase Therapeutics
Michael J. Fox Foundation
Michael J. Fox Foundation investment in Grant - Inhibikase Therapeutics
Georgia Research Alliance
Georgia Research Alliance investment in Grant - Inhibikase Therapeutics
Georgia Research Alliance
Georgia Research Alliance investment in Grant - Inhibikase Therapeutics
Georgia Research Alliance
Georgia Research Alliance investment in Grant - Inhibikase Therapeutics
Georgia Research Alliance
Georgia Research Alliance investment in Grant - Inhibikase Therapeutics
Georgia Research Alliance
Georgia Research Alliance investment in Grant - Inhibikase Therapeutics
Georgia Research Alliance
Georgia Research Alliance investment in Grant - Inhibikase Therapeutics
Georgia Research Alliance
Georgia Research Alliance investment in Grant - Inhibikase Therapeutics
Official Site Inspections
http://www.inhibikase.com Semrush global rank: 5.16 M Semrush visits lastest month: 1.56 K
- Host name: ec2-174-129-30-187.compute-1.amazonaws.com
- IP address: 174.129.30.187
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Inhibikase Therapeutics"
Inhibikase Therapeutics, Inc. - Drug pipelines, Patents, …
Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future …See details»
Inhibikase Therapeutics, Inc. (IKT)
Mar 27, 2025 We are Inhibikase Therapeutics, a pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary …See details»
Management Team :: Inhibikase Therapeutics, Inc. (IKT)
Chad Orevillo has over 30 years of experience in pharmaceutical clinical development and operations and program management. Prior to joining Inhibikase, he was co-founder and …See details»
Inhibikase Therapeutics - Overview, News & Similar companies
Inhibikase's multi-therapeutic pipeline focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's …See details»
Inhibikase Therapeutics - Crunchbase Company Profile & Funding
Inhibikase Therapeutics has developed the first small molecule platform capable of treating both bacterial and viral infectious diseases through a common mechanism of action in the host. The …See details»
Inhibikase Therapeutics, Inc. | LinkedIn
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course …See details»
Inhibikase Therapeutics, Inc. Company Profile | Atlanta, GA ...
Find company research, competitor information, contact details & financial data for Inhibikase Therapeutics, Inc. of Atlanta, GA. Get the latest business insights from Dun & Bradstreet.See details»
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA …
Feb 28, 2024 Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, …See details»
Inhibikase Announces Expansion of Senior Leadership Team
Feb 25, 2025 Inhibikase’s cardiopulmonary disease portfolio is led by IkT-001, an oral prodrug of imatinib mesylate, for PAH. Social Media Disclaimer Investors and others should note that the …See details»
Inhibikase Therapeutics - 2025 Company Profile - Tracxn
May 9, 2025 Inhibikase Therapeutics - Developer of host-targeted protein kinase inhibitors for infectious diseases. Public Company. Raised funding over 10 rounds from 2 investors. …See details»
Inhibikase Therapeutics - Craft
Inhibikase Therapeutics has 5 employees across 2 locations and $260.5 k in annual revenue in FY 2023. See insights on Inhibikase Therapeutics including office locations, competitors, …See details»
Inhibikase Therapeutics Announces First Quarter 2025 ... - BioSpace
May 15, 2025 Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing Abelson Tyrosine Kinase inhibitor therapeutics for Cardiopulmonary …See details»
Inhibikase Therapeutics Inc - Company Profile and News
Inhibikase Therapeutics, Inc. operates as a clinical stage pharmaceutical company. The Company focuses on developing and commercializing small-molecule kinase inhibitor therapeutics for …See details»
Inhibikase Therapeutics, Inc. Company Overview, Contact Details ...
Inhibikase Therapeutics, Inc. Pharmaceutical Manufacturing Georgia, United States 11-50 Employees. Inhibikase Therapeutics (Nasdaq: IKT) is a clinical-stage pharmaceutical company …See details»
Inhibikase Therapeutics - Funding, Financials, Valuation & Investors
Inhibikase Therapeutics is registered under the ticker NASDAQ:IKT . Their stock opened with $10.00 in its Dec 22, 2020 IPO. Inhibikase Therapeutics is funded by 14 investors. Blackstone …See details»
Inhibikase Therapeutics - Products, Competitors, Financials, …
Stifel Financial Corp Invests $43,000 in Inhibikase Therapeutics, Inc. (NYSE:IKT) May 17, 2025. Stifel Financial Corp Invests $43,000 in Inhibikase Therapeutics, Inc. (NYSE:IKT) Posted by …See details»
Inhibikase Therapeutics, Inc. (IKT) - Yahoo Finance Canada
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT …See details»
Inhibikase Therapeutics - Contacts, Employees, Board Members, …
Inhibikase Therapeutics is a developer of cellular Abelson tyrosine kinase inhibitors to treat infections and other diseases. New. Resources. Advanced Search. Start Free Trial . Talk With …See details»
Inhibikase Therapeutics Inc, IQT0:MUN profile - FT.com - Financial …
Oct 31, 2024 Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for …See details»
Inhibikase Therapeutics Announces Publication Highlighting …
Jan 29, 2024 Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, …See details»